RESUMO
Psoriasis is not a rare disease in the pediatric population. Early recognition and treatment is necessary to improve the physical and psychological symptoms of psoriasis and minimize its adverse effects on future health. In moderate-to-severe cases, treatment is challenging. There is no Food and Drug Administration (FDA)-approved systemic treatment for children and adolescents with moderate-to-severe plaque-type psoriasis other than topical corticosteroids, and current treatment is limited to the ones that are used in adults, which may have more severe side effects in children. Recently, there have been advances in the use of biologic therapies, specifically tumor necrosis factor (TNF)-alpha blockers, for pediatric autoimmune diseases and pediatric psoriasis. The present review will summarize the data on TNF inhibitors for pediatric psoriasis, as well as detail studies that led to the approval of biologics in other pediatric autoimmune diseases.
Assuntos
Produtos Biológicos/uso terapêutico , Psoríase/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adolescente , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/imunologia , Produtos Biológicos/efeitos adversos , Produtos Biológicos/imunologia , Criança , Fármacos Dermatológicos/efeitos adversos , Fármacos Dermatológicos/imunologia , Fármacos Dermatológicos/uso terapêutico , Aprovação de Drogas , Humanos , Psoríase/imunologia , Índice de Gravidade de Doença , Estados Unidos , United States Food and Drug AdministrationRESUMO
Dissecting cellulitis of the scalp (DCS) is a suppurative, neutrophillic dermatosis. Therapies typically provide short-term improvement and include antibiotics, prednisone, and isotretinoin, as well as radiation, surgical excision, and laser ablation. The authors report the use of the tumor necrosis factor (TNF) blocker, adalimumab, to successfully treat a 39-year-old male with a long-standing history of DCS.